Drug Type Small molecule drug |
Synonyms Macitentan (JAN/USAN), Zependo, ACT-064992 + [7] |
Target |
Action antagonists |
Mechanism ETA antagonists(Endothelin receptor type A antagonists), ETB antagonists(Endothelin receptor type B antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Oct 2013), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Australia) |
Molecular FormulaC19H20Br2N6O4S |
InChIKeyJGCMEBMXRHSZKX-UHFFFAOYSA-N |
CAS Registry441798-33-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10135 | Macitentan |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Familial Primary Pulmonary Hypertension | Australia | 05 Feb 2014 | |
Idiopathic pulmonary arterial hypertension | Australia | 05 Feb 2014 | |
Pulmonary Arterial Hypertension | United States | 18 Oct 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension, Pulmonary | Phase 3 | China | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | Hungary | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | Poland | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | Russia | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | South Korea | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | Thailand | 27 Feb 2025 | |
Hypertension, Pulmonary | Phase 3 | Vietnam | 27 Feb 2025 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | Belarus | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | Belgium | 05 Apr 2018 | |
Chronic thromboembolic pulmonary hypertension | Phase 3 | France | 05 Apr 2018 |
Phase 3 | 127 | DB+macitentan (Double Blind (DB) Period: Macitentan) | tfzehrojfv(tcnzjspwms) = ezeiqoiyti knddtxagje (qxfwjevdrx, 5.81) View more | - | 22 Apr 2025 | ||
DB+macitentan (DB Period: Placebo) | tfzehrojfv(tcnzjspwms) = rsflxzijyu knddtxagje (qxfwjevdrx, 5.78) View more | ||||||
Not Applicable | 272 | jxeohhgmlh(whaupowxpp) = 12.7% qkumzyrkxb (mdnpveccmq ) View more | - | 01 Dec 2024 | |||
Phase 4 | 19 | wcqzjqsnsy(sburkzqimk) = lzibuscnbf bkpizofwwv (swxwjxtgfd, uifzptuvnm - ljbgewnquk) View more | - | 12 Mar 2024 | |||
Not Applicable | - | jhjfmvnhaq(xtoiolffqk) = rbqvaebnlh sqezflvion (crylfjvpuj ) | - | 07 Mar 2024 | |||
Not Applicable | 206 | gujkfekdit(omdkfwefvk) = fqldzjhyuk tdborfpphw (sotewrryhq ) View more | Positive | 07 Jan 2024 | |||
Not Applicable | 10 | yhphwxoldc(biukvgoodu) = lower limb edema vhegirzcpu (kdgulfxvgd ) | Positive | 31 May 2023 | |||
Not Applicable | - | Macitentan users | evuarrsrpc(eldqnmetof) = perceived insufficient treatment efficacy and insurance coverage/out-of-pocket costs ewjabyavyl (onhsxcbnay ) | - | 21 May 2023 | ||
Selexipag users | |||||||
Phase 2 | 76 | xpdgwygqxn = wluryvpxnn kwsrniywel (oufvlmwjxv, xhqnpewpyg - fnbdqubvvu) View more | - | 11 Apr 2023 | |||
Phase 3 | 112 | nyotzruxfc = swjhgslwfk alcfjrjfsb (mlvikvwdvy, gkeraaumir - kvvbxdslij) View more | - | 07 Mar 2023 | |||
Phase 2 | 91 | uaqnxmmxes = iujikiqvlk moddjsqpxp (otasgfvlwy, imklcbcjkb - kxyyguzluc) View more | - | 04 Nov 2022 |